Reviews thymosin β4’s actin-binding, cell-migration and regenerative biology.
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.
Expert opinion on biological therapy · 2012
PubMed ↗ (opens in a new tab)
Recovery & Repair
Recovery plus calm inflammation
The GLOW blend with KPV added for a stronger anti-inflammatory and gut-healing effect.
Ships as a freeze-dried powder. Need water to mix it? Add Reconstitution Solution.
The science
Evidence level
1/5
Preclinical
Each ingredient has its own cell and animal research; the four-peptide blend has not been studied as a combination.
100%7
of KPV-treated mice rescued from death in a severe colitis model
VEGFR23
blood-vessel growth pathway activated by BPC-157
p63+4
stem-like basal skin cells increased by GHK-Cu
Mechanism of action
Targets & pathways
KPV enters intestinal and immune cells through the PepT1 transporter and, at nanomolar concentrations, inhibits NF-κB and MAP kinase inflammatory signalling1.
GHK-Cu increases integrin expression and stem-like basal cells in human skin models4.
Thymosin β4, TB-500’s parent molecule, binds actin and promotes the cell migration that closes wounds5.
What the research shows
Reviews thymosin β4’s actin-binding, cell-migration and regenerative biology.
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.
Expert opinion on biological therapy · 2012
PubMed ↗ (opens in a new tab)BPC-157 cell and rat work implicated VEGFR2 signalling.
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
Journal of molecular medicine (Berlin, Germany) · 2017
PubMed ↗ (opens in a new tab)KPV cell and mouse experiments linked PepT1 uptake to inflammatory-signalling changes.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Gastroenterology · 2008
PubMed ↗ (opens in a new tab)Questions
KLOW adds KPV’s inflammation-related laboratory rationale. No controlled comparison shows that it is stronger or safer.
The cited KPV findings are cell and animal research, not an approved clinical gut-disease indication for the blend.
A single-component or different-combination report does not establish a result for the KLOW formulation.
No. Adding a component adds formulation and safety questions without automatically adding clinical benefit.
The blend includes additional experimental components; no cited comparison determines an advantage over KPV alone.
Recovery & Repair
Recovery & Repair
Recovery & Repair
Recovery & Repair